Immuneering to Present at the ESMO Congress 2026
Immuneering announced that a trial-in-progress abstract on the Phase 3 MAPKeeper 301 trial of atebimetinib plus mGnP in first-line pancreatic cancer was accepted for poster presentation at ESMO Congress 2026. The poster will be presented October 25, 2026, in Madrid, led by Eileen M. O'Reilly of Memorial Sloan Kettering; full abstracts publish October 19.
Key figures
- Drug Name
- atebimetinib
- Phase Of Trial
- Phase 3
- Indication
- first-line pancreatic cancer
- Nct number
- NCT07562152
- Trial name
- MAPKeeper 301
- Poster number
- 3189TiP
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.